We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Several days after Valeant Pharmaceuticals International executives pledged to establish a committee to review its drug pricing practices, the Senate Aging Committee released a treasure trove of documents related to the company’s internal pricing strategies. Read More
Valeant Pharmaceuticals International has established a drug pricing committee, a move that comes a week after company representatives pledged to review its pricing model in the face of withering congressional criticism. Read More
Two FDA advisory committees recommended the FDA approve KemPharm’s opioid pill Apadaz, even though they rejected an abuse-deterrent label for the candidate. Read More
Two FDA advisory committees voted unanimously to recommend modifications to the REMS for extended-release and long-acting opioids, although the recommendation did not get into specific courses of action. Read More
The FDA is looking to shed light on the sometimes murky rules governing compounding operations to distinguish heavily regulated outsourcing facilities from tiny compounding operations that are lightly regulated. Read More
Janssen has moved to a continuous manufacturing process at one of its facilities after getting the green light April 8 from the FDA to switch from batch production, making it the first drugmaker allowed to change its production method mid-cycle. Read More